Last €130.34 EUR
Change Today +0.60 / 0.46%
Volume 10.0
UTH On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:58 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

united therapeutics corp (UTH) Snapshot

Open
€130.02
Previous Close
€129.74
Day High
€130.34
Day Low
€127.05
52 Week High
01/23/15 - €131.92
52 Week Low
06/18/14 - €62.62
Market Cap
6.2B
Average Volume 10 Days
25.3
EPS TTM
--
Shares Outstanding
47.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for UNITED THERAPEUTICS CORP (UTH)

united therapeutics corp (UTH) Related Businessweek News

View More BusinessWeek News

united therapeutics corp (UTH) Details

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

706 Employees
Last Reported Date: 02/25/14
Founded in 1996

united therapeutics corp (UTH) Top Compensated Officers

Founder, Chairman and Co-Chief Executive Offi...
Total Annual Compensation: $992.7K
Co-Chief Executive Officer, President and Dir...
Total Annual Compensation: $808.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $543.8K
Executive Vice President of Strategic Plannin...
Total Annual Compensation: $702.9K
Compensation as of Fiscal Year 2013.

united therapeutics corp (UTH) Key Developments

United Therapeutics and DEKA Sign Agreement to Develop PAH Drug Delivery System

United Therapeutics Corporation has signed an agreement with DEKA R&D Corp. to develop a new technology for subcutaneous delivery of Remodulin injection to patients with pulmonary arterial hypertension, or PAH, via a pre-filled semi-disposable pump system.

United Therapeutics Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 04:00 PM

United Therapeutics Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 04:00 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Martine A. Rothblatt, Founder, Chairman and Co-Chief Executive Officer, Roger A. Jeffs, Co-Chief Executive Officer, President and Director.

United Therapeutics Corporation Announces Executive Promotions, Effective January 1, 2015

United Therapeutics Corporation announced two senior executive promotions. Senior Executive promotions: the company announced the promotion of Roger Jeffs, Ph.D. to President and Co-Chief Executive Officer and David Zaccardelli, Pharm. D. to Executive Vice President and Chief Operating Officer. In connection with these promotions, Dr. Rothblatt's title will change from Chairman and Chief Executive Officer to Chairman and Co-Chief Executive Officer. As Chairman of the Board and Co-Chief Executive Officer, Dr. Rothblatt will continue to serve as the principal executive officer of the company. These title changes will become effective January 1, 2015. Dr. Jeffs joined United Therapeutics in 1998 and currently serves as the company's President and Chief Operating Officer, a position he has held since 2001. Dr. Zaccardelli currently serves as Chief Manufacturing Officer and EVP, Pharmaceutical Development, a position he has held since 2008.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UTH:GR €130.34 EUR +0.60

UTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.100.70 CHF +1.45
Alexion Pharmaceuticals Inc $180.36 USD 0.00
Celanese Corp $54.26 USD -0.69
Nippon Shinyaku Co Ltd ¥3,770 JPY -10.00
Vertex Pharmaceuticals Inc $123.67 USD 0.00
View Industry Companies
 

Industry Analysis

UTH

Industry Average

Valuation UTH Industry Range
Price/Earnings 41.2x
Price/Sales 5.6x
Price/Book 5.9x
Price/Cash Flow 35.9x
TEV/Sales 4.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNITED THERAPEUTICS CORP, please visit www.unither.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.